Schering-Plough makes changes in its R&D operations

Schering-Plough has made several changes in its research and development operations. Thomas Koestler, Ph.D., was promoted to executive vice president, global development, Schering-Plough Research Institute (SPRI) and James MacDonald, Ph.D., was promoted to executive vice president, preclinical development, SPRI; both report to Cecil Pickett, Ph.D., senior vice president and president, SPRI. Koestler and MacDonald will both continue as members of the Operations Management Team (OMT), also.
Koestler will set strategic direction and implementation plans for the new development organization, which will include worldwide clinical development, pharmaceutical sciences, global regulatory affairs and global project management. Before joining Schering-Plough in 2003 as executive vice president, global regulatory affairs and global project management, Koestler was senior vice president, global regulatory affairs, Pharmacia Corporation.
MacDonald will continue to have direct responsibility for the drug safety and metabolism group as well as the newly created SPRI computer validation group. He will be responsible for assuring a steady flow of new compounds for the development pipeline by establishing effective working relationships with the appropriate groups in discovery, pharmaceutical sciences and clinical research. MacDonald joined Schering-Plough in 1994 as senior vice president, drug, safety and metabolism.
"These changes are designed to further strengthen Schering-Plough Research Institute's development operations worldwide, as we transform the company into a successful global competitor beginning with our anticipated turnaround this year," said Fred Hassan, chairman and chief executive, Schering-Plough.
You must be a registered member of MMM to post a comment.

Content marketing is not advertising in the old sense. In its use of social media, content marketing challenges consumers while relying on their input. It is proactive and responsive to their concerns, needs and energy. Content marketing has become the new voice of marketing. Learn what you need to know and how pharma marketers can adapt to this innovative venture into social media by clicking here for access.

Email Newsletters